Immunotherapy for solid tumors, especially “immunologically cold tumors” like breast and prostate cancer, has often failed due to the complex immunosuppressive tumor microenvironment neutralizing an antitumor immune response. Our therapeutic not only recruits potent anti-tumor immune cells, but also inhibits multiple key immunosuppressive factors in the tumor microenvironment. Our technology even has the potential to improve efficacy of prior promising therapies that have failed in the clinic.